HIV-1-associated dementia: A basic science and clinical perspective

AIDS Reader

Volumn 12, Issue 8, 2002, Pages 358-368

  Diesing, Thomas S ^a   Swindells, Susan ^a   Gelbard, Harris ^a   Gendelman, Howard E ^a  

^a MAYO CLINIC   (United States)

Author keywords

HIV 1 associated cognitive dysfunction; HIV 1 associated dementia; HIV AIDS; Macrophages; Microglia; Neurotoxins

Indexed keywords

ANTIRETROVIRUS AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROTOXIN; PRAMIPEXOLE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; VALPROIC ACID; ZIDOVUDINE;

BEHAVIOR DISORDER; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; INCIDENCE; METABOLIC ENCEPHALOPATHY; MICROGLIA; MONONUCLEAR PHAGOCYTE; MOTOR DYSFUNCTION; NONHUMAN; REVIEW; T LYMPHOCYTE; VIRUS LOAD;

AIDS DEMENTIA COMPLEX; CENTRAL NERVOUS SYSTEM; HIV-1; HUMANS; NEURONS;

EID: 0036678041     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. The AIDS dementia complex, I: Clinical features
2. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998
3. Cortical dendritic pathology in human immunodeficiency virus encephalitis
4. Neuronal loss in the frontal cortex in HIV infection
5. Clinical neuropathologic correlation in HIV-associated dementia
6. Multinucleated giant cells in the brain: A hallmark of the acquired immunodeficiency syndrome (AIDS)
7. Primary human T-lymphotropic virus type III infection
8. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: Implications for the neuropathogenesis of HIV disease
9. The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes
10. Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlations with dementia
11. HIV-associated dementia
12. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid
13. The cell biology of the blood-brain barrier
14. Astrocytes induce blood-brain barrier properties in endothelial cells
15. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families
16. Expression and localization of messenger RNA and protein for monocyte chemoattractant protein-1 in human malignant glioma
17. Tumor necrosis factor alpha induces adhesion molecule expression on human fetal astrocytes
18. Recombinant human interleukin-1 induces meningitis and blood-brain barrier injury in the rat: Characterization and comparison with tumor necrosis factor
19. Inflammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes: Two distinct pathways of the gene expression
20. Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: Immunohistochemica] localization of serum proteins in postmortem brain
21. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy
22. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients
23. Persistent human immunodeficiency virus type 1 infection in human fetal glial cells reactivated by T-cell factor(s) or by the cytokines tumor necrosis factor alpha and interleukin-1 beta
24. Sequences regulating tropism of human immunodeficiency virus type 1 for brain capillary endothelial cells map to a unique region on the viral genome
25. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes
26. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain
27. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor
28. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120
29. Relation of phenotype evolution of HIV-1 to envelope V2 configuration
30. + cells is mediated by the chemokine receptor CC-CKR-5
31. Identification of a major co-receptor for primary isolates of HIV-1
32. CD14lowCD16high: A cytokine producing monocyte subset which expands during human immunodeficiency virus infection
33. Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy
34. Bone marrow derived elements and resident microglia in brain inflammation
35. Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method
36. Microglia in human disease, with an emphasis on the acquired immune deficiency syndrome
37. Detection of HLA-DR in human microglia is dependent on clinical and technical factors
38. Pathways to neuronal injury and apoptosis in HIV-associated dementia
39. Cytokine-stimulated, but not HIV-infected, human monocyte-derived macrophages produce neurotoxic levels of 1-cysteine
40. Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: Implications for HIV-associated neurological disease
41. Neuronal apoptosis in HIV infection in adults
42. T-lymphocyte entry into the central nervous system
43. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis
44. Stages of restricted HIV-1 infection in astrocyte cultures derived from human fetal brain tissue
45. gp120-Induced alterations of human astrocyte function: Na(+)/H(+) exchange, K(+) conductance, and glutamate flux
46. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes: Implications for pathogenesis of HIV-1 dementia
47. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes
48. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia
49. Immunologic NO synthase: Elevation in severe AIDS dementia and induction by HIV-1 gp41
50. Differential regulation and function of Fas expression on glial cells
51. Neuronal apoptosis in human immunodeficiency virus infection
52. Lymphotropic virions affect chemokine receptor-mediated neural signaling and apoptosis: Implications for human immunodeficiency virus type 1-associated dementia
53. Immunohistochemical analysis of CCR2, CCR3, CCR5, and CXCR4 in the human brain: Potential mechanisms for HIV dementia
54. Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha mediated by the chemokine receptor CXCR4
55. Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia
56. Chemokine and chemokine receptor expression in the central nervous system
57. Neuronal apoptosis induced by HIV-1 Tat protein and TNF-alpha: Potentiation of neurotoxicity mediated by oxidative stress and implications for HIV-1 dementia
58. Soluble HIV-1 infected macrophage secretory products mediate blockade of long-term potentiation: A mechanism for cognitive dysfunction in HIV-1-associated dementia
59. Synergistic effects of the HIV coat protein and NMDA receptor-mediated neurotoxicity
60. Mobilization of intracellular calcium stores participates in the rise of [Ca2+]i and the toxic actions of the HIV coat protein GP120
61. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: Protection by memantine
62. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors
63. Extracellular HIV-1 virus protein R causes a large inward current and cell death in cultured hippocampal neurons: Implications for AIDS pathology
64. Oxidative stress and neuroAIDS: Triggers, modulators and novel antioxidants
65. Release of nitric oxide from astroglial cells: A key mechanism in neuroimmune disorders
66. Increased peroxynitrate activity in AIDS dementia complex: Implications for the neuropathogenisis of HIV-1 infection
67. Oxidative stress, glutamate, and neurodegenerative disorders
68. Neuronal fractalkine expression in HIV-1 encephalitis: Roles for macrophage recruitment and neuroprotection in the central nervous system
69. The HNRC 500-neuropsychology of HIV infection at different disease stages
70. Assessing HIV-associated dementia: Modified HIV dementia scale versus the Grooved Pegboard
71. Structural, functional and molecular neuroimaging in AIDS
72. Comparison of magnetic resonance imaging with neuropathological findings in the diagnosisof HIV and CMV associated CNS disease in AIDS
73. Highly active antiretroviral therapy reversesbrain metabolite abnormalities in mild HIV dementia
74. Proton MR spectroscopy of HIV-infected patients: Characterization of abnormalities with imaging and clinical correlation
75. Proton MR spectroscopy of the brain in AIDS dementia complex
76. Prospective utility of cerebral proton magnetic resonance spectroscopy in monitoring HIV infection and its associated neurological impairment
77. Reduced brain N-acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus-seropositive individuals: In vivo 1H magnetic resonance spectroscopic imaging
78. In vivo proton MRS studies of HIV brain injury and HIV-dementia
79. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding
80. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions
81. Distribution of brain HIV load in AIDS
82. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
83. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
84. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy
85. Highly active antiretroviral treatment in HIV infection: Benefits for neuropsychological function
86. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy
87. Pharmacological frontiers in the treatment of AIDS dementia
88. Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy
89. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia
90. HIV-associated dementia: New insights into disease pathogenesis and therapeutic interventions
91. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy
92. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir
93. Changes in CSF and plasma HIV-1 RNA and in neuropsychological test performance after starting HAART
94. Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir
95. Time course of cerebrospinal fluid responses to antiretroviral therapy: Evidence for variable compartmentalization of infection
96. Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy
97. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
98. Human immunodeficiency virus 1 protease inhibitors in clinical practice: Predictors of virological outcome
99. Determinants of virological response to antiretroviral therapy: Implications for long-term strategies
100. Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons
101. HIV-1 Tat mediated activation of glycogen synthase kinase-3b (GSK-3b) contributes to Tat-mediated neurotoxicity
102. Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro
103. HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures
104. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity
105. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells
106. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion
107. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons
108. Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole
109. Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study
110. Clinical trials in HIV-associated cognitive impairment: Cognitive and functional outcomes